Spectral MD Holdings’ CEO, Wensheng Fan talked to Proactive about a new partnership with US Federal agency BARDA (Biomedical Advanced Research and Development Authority) in Washington.
Through the partnership Spectral MD hopes to be able to accelerate the commercialisation of its ‘DeepView’ technology, allowing the AI prediction of the wound healing process to be available to people globally.
It takes the value of BARDA funding for the company since 2013 to more than US$100mln, he said.